Get the latest NAV of WhiteOak Capital Pharma and Healthcare Fund Direct Growth. View historical returns compared to its benchmark and category average. Know which stocks and sectors the fund is investing in. Get an estimate of returns from the SIP and lump sum returns calculator. View detailed holding analysis and peer comparison. Get INDmoney ranking of the fund.
₹13.11
1D
NAV as on 16 May 2025
23.66%/per year
Since Inception
▲▼
583 people have invested ₹ 34.9L in WhiteOak Capital Pharma and Healthcare Fund Direct Growth in the last three months
Fund returns vs Benchmark returns vs Category Average returns as on (16-May-25)
The fund has outperformed the benchmark (Nifty 500) over 1Y, but underperformed over 3Y, 5Y.
Calculate SIP and lumpsum returns based on historical performance
Total Investment
0
Profit
Total Corpus
0
See fund asset allocation details as on (13-May-25)
Fund Distribution
as on (13-May-25)
Equity 93.3%
Debt & Cash 6.7%
See fund sector allocation details as on (13-May-25)
Sector Allocation
Equity 93.3%
Debt & Cash 6.7%
Top 3 Sectors in April were Health, Basic Materials & Financial Services
Health
96%
Government
18%
Basic Materials
4%
Health
95%
Basic Materials
4%
Financial Services
as on (30-Apr-25)
Equity
Debt & Cash
Get key fund statistics, minimum investment details, AUM, expense ratio, exit load, and tax treatment.
Expense ratio | 0.68% |
Benchmark | BSE Healthcare TR INR |
AUM | ₹320 Cr |
Inception Date | 6 February, 2024 |
Min Lumpsum/SIP | ₹500/₹100 |
Exit Load | 1.0% |
Lock In | No Lock-in |
TurnOver | 73.27% |
STCG | Selling mutual fund before 1 year, returns taxed at 20%. |
LTCG | After 1 year, 12.5% tax on returns over ₹1.25 lakh/year. |
Risk | Very High Risk |
WhiteOak Capital Pharma and Healthcare Fund Direct Growth is an equity fund. This fund was started on 6 February, 2024. The fund is managed by Piyush Baranwal. The fund could potentially beat inflation in the long-run.
WhiteOak Capital Pharma and Healthcare Fund Direct Growth has given a CAGR return of 23.66% since inception. Over the last 1 year the fund has given a CAGR return of 28.15%.
WhiteOak Capital Pharma and Healthcare Fund Direct Growth has allocated its funds majorly in Health, Cash Equivalent, Government, Basic Materials, Financial Services. Its top holdings are Sun Pharmaceuticals Industries Ltd, Cipla Ltd, Divi's Laboratories Ltd, Max Healthcare Institute Ltd Ordinary Shares, Lupin Ltd
As it is a sector - healthcare mutual fund the taxation is as follows:For short term (less than a year) capital gains will be taxed at 20%For long term (more than 1 year) capital gains will be taxed at 12.5% without indexation benefitDividends will always be taxed at slab rate. Long term gains upto Rs 1 lakh are exempt capital gains tax.
The primary objective of the Scheme is to provide long-term capital appreciation by investing predominantly in equity and equity related instruments of Pharma and Healthcare companies. However, there can be no assurance that the investment objective of the Scheme will be realized.
Minimum investment for lump sum payment is INR 500.00 and for SIP is INR 100.00. WhiteOak Capital Pharma and Healthcare Fund Direct Growth has no lock in period.
Fund Manager of WhiteOak Capital Pharma and Healthcare Fund Direct Growth, since 6 February 2024
1Y CAGR
▲ 16.17
1Y CAGR
▲ 16.99
1Y CAGR
▲ 17.80
1Y CAGR
▲ 15.00
1Y CAGR
▲ 16.97
WhiteOak Capital Pharma and Healthcare Fund Direct Growth | Absolute Returns | CAGR Returns |
1 Month Returns | 2.01% | 2.01% |
6 Month Returns | 1.33% | 1.33% |
1 Year Returns | 28.15% | 28.15% |
3 Years Returns | 0% | 0% |
Fund Name | Alpha 1 Year | Alpha 3 Years | Alpha 5 Years |
WhiteOak Capital Pharma and Healthcare Fund Direct Growth | 8 | - | - |
Fund Name | Beta 1 Year | Beta 3 Years | Beta 5 Years |
WhiteOak Capital Pharma and Healthcare Fund Direct Growth | 1 | - | - |
Fund Name | Sharpe Ratio 1 Year | Sharpe Ratio 3 Years | Sharpe Ratio 5 Years |
WhiteOak Capital Pharma and Healthcare Fund Direct Growth | 1.03 | - | - |
Fund Name | Standard Deviation 1 Year | Standard Deviation 3 Years | Standard Deviation 5 Years |
WhiteOak Capital Pharma and Healthcare Fund Direct Growth | 20.35 | - | - |